Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study

Immunologic Research

Volumn 65, Issue 1, 2017, Pages 419-422

  Benucci, Maurizio ^a   Gobbi, Francesca Li ^a   Bandinelli, Francesca ^a   Damiani, Arianna ^a   Infantino, Maria ^b   Grossi, Valentina ^b   Manfredi, Mariangela ^b   Parisi, Simone ^c   Fusaro, Enrico ^c   Batticciotto, Alberto ^d   Sarzi Puttini, Piercarlo ^d   Atzeni, Fabiola ^d   Meacci, Francesca ^b  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b Hospital S Giovanni di Dio   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Biosimilar; CT P13; Spondyloarthritis; Switching

Indexed keywords

BIOSIMILAR AGENT; INFLIXIMAB; ANTIBODY; ANTIRHEUMATIC AGENT;

ADULT; AGED; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL ARTICLE; DAS28; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; MALE; MORNING STIFFNESS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUSTULOSIS PALMOPLANTARIS; SPONDYLARTHRITIS; VISUAL ANALOG SCALE; ANKYLOSING SPONDYLITIS; BLOOD; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLIXIMAB; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 84979496968     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-016-8843-5     Document Type: Article

References (20)

1. WHO, World Health Organization. Expert Committee on Biological Standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 19 Feb 2015.
2. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicine Products (CHMP/437/04 Rev 1). 23 October 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 2 Jul 2015.
3. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. April 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 2 Jul 2015.
4. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42:177–83.
5. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. mAbs. 2014;6:1163–77.
6. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–12.
7. Ebbers HC, Crow SA, Vulto AG, et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol. 2012;30:1186–90.
8. Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ. 2014;15(Suppl. 1):S5–11.
9. AIFA: Position paper. I farmaci biosimilari. 13/05/2013.
10. Atzeni F, Sebastiani M, Ricci C, Celano A, Gremese E, Iannone F, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs. Clin Exp Rheumatol. 2015;33(1):1–4.
11. Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2015-208783.
12. Meacci F, Manfredi M, Infantino M, Grossi V, Benucci M. Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2016-210078.
13. Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016
14. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44(4):257–66. doi:10.1016/j.biologicals.2016.03.006.
15. Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–12. doi:10.1111/jgh.12997.
16. Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl. 1):35e44.
17. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a Biosimilar to Infliximab in patients with inflammatory Bowel disease: a case series. Dig Dis Sci. 2015;60:6.
18. Sieczkowska J, Jarze˛bicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska A, et al. Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease. Preliminary observation. J Crohns Colitis. 2016;10(2):127–32. doi:10.1093/ecco-jcc/jjv233.
19. Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–83.
20. Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, de Stefano R, et al. Switch from Infliximab to Infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Expert Opin Biol Ther. 2016. doi:10.1080/14712598.2016.1198765.